Bone metastasis predicts poor prognosis of patients with brain metastases from colorectal carcinoma post aggressive treatment

被引:3
|
作者
Duan, Hao [1 ]
He, Zhen-Qiang [1 ]
Guo, Cheng-Cheng [1 ]
Li, Jue-Hui [1 ]
Wang, Jian [1 ]
Zhu, Zhe [2 ]
Sai, Ke [1 ]
Chen, Zhong-Ping [1 ]
Jiang, Xiao-Bing [1 ]
Mou, Yong-Gao [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Neurosurg Neurooncol,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China
[2] Univ Calif San Diego, Sch Med, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA
来源
基金
中国国家自然科学基金;
关键词
brain metastasis; colorectal cancer; bone metastasis; aggressive treatment; CANCER; RESECTION; SURGERY;
D O I
10.2147/CMAR.S169563
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The presence of brain metastasis (BM) in patients with colorectal cancer (CRC) is usually associated with terminal-stage illness; however, a subgroup of patients receiving aggressive treatment can have a satisfactory prognosis. This study was designed to investigate the profile of prognostic factors in CRC patients with BM treated aggressively. Patients and methods: CRC patients with BM were retrospectively reviewed. Survival analysis was performed to identify potential prognostic factors in the entire cohort of patients and a subgroup of patients treated aggressively. Aggressive treatments included surgical resection, radiotherapy, and/or chemotherapy. Overall survival was defined as the time between the diagnosis of BM and death or until the date of the last follow-up visit. Results: A total of 78 CRC patients were confirmed as having BM. Sixty-eight of them had extracranial metastases at the time of their BM diagnosis. The most common sites of extracranial metastases were lung (n=51, 65.4%), followed by liver (n=25, 32.1%) and bone (n=12, 15.4%). Fifty-one patients who were treated aggressively had significantly longer overall survival than those who accepted palliative care (14.1 months vs 2.0 months, P<0.0001). Multivariate analysis was applied, and the results showed that aggressive treatment (n=51), recursive partitioning analysis class I/II (hazard ratio [HR]=0.27, 95% CI: 0.12-0.6, P=0.001), and fewer BM (HR=0.4, 95% CI: 0.21-0.78, P=0.07) predicted longer survival. In contrast, the presence of bone metastasis, rather than lung or liver metastasis, at the time of diagnosis of BM (HR=2.38, 95% CI: 1.08-5.28, P=0.032) predicted a poor prognosis. Conclusions: Although the prognosis of CRC patients having BM is frequently very poor, those with good performance status and few brain lesions responded to aggressive treatment, while those with bone metastasis at the time of diagnosis of BM had relatively dismal survival rates, even when treated aggressively.
引用
收藏
页码:2467 / 2474
页数:8
相关论文
共 50 条
  • [21] CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma
    Jiang, Guoqing
    Zhang, Long
    Zhu, Qin
    Bai, Dousheng
    Zhang, Chuanyong
    Wang, Xuehao
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [22] Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma
    Mitsui, Yozo
    Shiina, Hiroaki
    Kato, Taku
    Maekawa, Shigekatsu
    Hashimoto, Yutaka
    Shiina, Marisa
    Imai-Sumida, Mitsuho
    Kulkarni, Priyanka
    Dasgupta, Pritha
    Wong, Ryan Kenji
    Hiraki, Miho
    Arichi, Naoko
    Fukuhara, Shinichiro
    Yamamura, Soichiro
    Majid, Shahana
    Saini, Sharanjot
    Deng, Guoren
    Dahiya, Rajvir
    Nakajima, Koichi
    Tanaka, Yuichiro
    MOLECULAR CANCER RESEARCH, 2017, 15 (07) : 884 - 895
  • [23] CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma
    Guoqing Jiang
    Long Zhang
    Qin Zhu
    Dousheng Bai
    Chuanyong Zhang
    Xuehao Wang
    Journal of Experimental & Clinical Cancer Research, 35
  • [24] Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis
    Sutton, CD
    O'Byrne, K
    Goddard, JC
    Marshall, LJ
    Jones, L
    Garcea, G
    Dennison, AR
    Poston, G
    Lloyd, DM
    Berry, DP
    CLINICAL CANCER RESEARCH, 2005, 11 (18) : 6567 - 6573
  • [25] SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases
    Mizuno, Takashi
    Cloyd, Jordan M.
    Vicente, Diego
    Omichi, Kiyohiko
    Chun, Yun Shin
    Kopetz, Scott E.
    Maru, Dipen
    Conrad, Claudius
    Tzeng, Ching-Wei D.
    Wei, Steven H.
    Aloia, Thomas A.
    Vauthey, Jean-Nicolas
    EJSO, 2018, 44 (05): : 684 - 692
  • [26] TRPM7 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor metastasis
    Chen, Jian-Peng
    Sun, Guiqin
    Wang, Wei-Bo
    Wang, Cai-Xia
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis
    Zhang, Lingyun
    Teng, Yuee
    Zhang, Ye
    Liu, Jing
    Xu, Ling
    Qu, Jinglei
    Hou, Kezuo
    Yang, Xianghong
    Liu, Yunpeng
    Qu, Xiujuan
    JOURNAL OF CLINICAL PATHOLOGY, 2012, 65 (01) : 36 - 40
  • [28] PDRG1 predicts a poor prognosis and facilitates the proliferation and metastasis of colorectal cancer
    Xu, Yixin
    Liu, Jia
    Jiang, Tao
    Shi, Linsen
    Shang, Liang
    Song, Jun
    Li, Leping
    EXPERIMENTAL CELL RESEARCH, 2021, 409 (02)
  • [29] Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis
    Yu, Suyang
    Bian, Honglei
    Gao, Xin
    Gui, Lin
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 41 (04) : 2185 - 2192
  • [30] FDG PET Predicts the Effects of 131I and Prognosis for Patients with Bone Metastases from Differentiated Thyroid Carcinoma
    Wang, Danyang
    Bai, Yongli
    Huo, Yanlei
    Ma, Chao
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13223 - 13232